Payment overview · 2025
General Payments
$59.12
4 reported records · 1 companies
Healthcare provider profile · identity verified
Katie B Fee, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENWOOD, SC · NPI 1083027650
Verified facts
What the public records show
CMS Open Payments records show Katie B Fee, MD received $59.12 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.12 | 100.0% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $59.12 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.12 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.12 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 273 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 258 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 50 |
| Lisinopril | Lisinopril | 185 | 49 |
| Gabapentin | Gabapentin | 159 | 33 |
| Losartan Potassium | Losartan Potassium | 154 | 36 |
| Omeprazole | Omeprazole | 142 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 40 |
| Montelukast Sodium | Montelukast Sodium | 132 | 39 |
| Metformin Hcl | Metformin Hcl | 131 | 37 |
| Famotidine | Famotidine | 118 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 29 |
| Simvastatin | Simvastatin | 109 | 29 |
| Furosemide | Furosemide | 105 | 35 |
| Potassium Chloride | Potassium Chloride | 105 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 25 |
| Metformin Hcl Er | Metformin Hcl | 82 | 22 |
| Alendronate Sodium | Alendronate Sodium | 74 | 19 |
| Meloxicam | Meloxicam | 65 | 14 |
| Glipizide Er | Glipizide | 64 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 18 |
| Donepezil Hcl | Donepezil Hcl | 61 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 16 |
| Bupropion Xl | Bupropion Hcl | 59 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 20 |
| Ezetimibe | Ezetimibe | 54 | 13 |
| Sertraline Hcl | Sertraline Hcl | 53 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 15 |
| Prednisone | Prednisone | 51 | 22 |
| Pregabalin | Pregabalin | 49 | 14 |
| Trazodone Hcl | Trazodone Hcl | 49 | 16 |
| Meclizine Hcl | Meclizine Hcl | 46 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 20 |
| Spironolactone | Spironolactone | 44 | 12 |
| Verapamil Er | Verapamil Hcl | 43 | 11 |
| Celecoxib | Celecoxib | 42 | 11 |
| Tramadol Hcl | Tramadol Hcl | 42 | 17 |
| Amoxicillin | Amoxicillin | 38 | 35 |
| Cephalexin | Cephalexin | 38 | 29 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 12 |
| Estradiol | Estradiol | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Eliquis | Apixaban | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Clonazepam | Clonazepam | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59.12 · 4 records | PFIZER INC. | NURTEC ODT, ZAVZPRET | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error